Biotechnology company Flex Pharma Inc (Nasdaq:FLKS) on Friday announced positive voting response relating to its planned merger with Salarius Pharmaceuticals LLC.

Flex Pharma said that at its special meeting of stockholders, all proposals were approved with regard to its planned merger with Salarius Pharmaceuticals LLC.

In conjunction, Flex Pharma added that it will file a Form 8-K to disclose detailed voting results for each proposal and expects to complete the merger within the next week or two.

Salarius Pharmaceuticals LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma. It has also received the US Food and Drug Administration's orphan drug designation and paediatric rare disease designation for Seclidemstat.